Ichosia Biotechnology is developing a scalable method of mass-producing an enhanced red blood product, Erythrosyn, by leveraging proprietary genetic engineering techniques. Erythrosyn is created by genetically engineering human stem cells to transform into fully functioning red blood cell. By transitioning this natural erythropoietin process from the body into the laboratory, Erythrosyn is being designed to be producible on demand, universally compatible and more cost effective than donor blood.
Company Details
- Founded
- -
- Address
- Worcester, Massachusetts 01605, Us
- Industry
- Biotechnology
- Website
- ichosia.com
- Keywords
- Philadelphia.
- HQ
- Worcester, Massachusetts
Ichosia Biotechnology Questions
Ichosia Biotechnology's website is ichosia.com
Ichosia Biotechnology's LinkedIn profile is https://www.linkedin.com/company/ichosia
Ichosia Biotechnology's industry is
Biotechnology
Ichosia Biotechnology's top competitors are
Biotechnology Advisors,
Kyinno Biotechnology, Inc.,
Strother Enterprises Inc.,
Syncell Biotechnology,
Kymera Therapeutics,
Massachusetts Biomedical Initiatives (Mbi),
Verve Therapeutics,
Revolution Biomanufacturing Inc.,
Advirna,
Dynamicure Biotechnology.
Ichosia Biotechnology's categories are Biotechnology
Ichosia Biotechnology's founding year is 2019
